trending Market Intelligence /marketintelligence/en/news-insights/trending/nyaVLHSKz8WFUE9cx-dA7A2 content esgSubNav
In This List

Coherus, Daiichi Sankyo end Enbrel biosimilar license deal

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Coherus, Daiichi Sankyo end Enbrel biosimilar license deal

Coherus Biosciences Inc. and Daiichi Sankyo Co. Ltd. terminated their contract regarding Coherus' Enbrel biosimilar product candidate CHS-0214.

The contract termination is due to Daiichi Sankyo's recent decision to discontinue development of CHS-0214 in Japan.

Coherus will not incur any early termination penalties.

Amgen Inc.'s Enbrel, or etanercept, is used to treat patients with moderately to severely active rheumatoid arthritis.